A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)

Key Inclusion Criteria: * Diagnosis of MDS according to World Health Organization (WHO) criteria confirmed by bone marrow aspirate and biopsy within 12 weeks before randomization. * Revised International Prognostic Scoring System (IPSS-R) very low, low, or intermediate risk MDS * HTB: Participants requiring ≥ 4 units of packed red blood cell (pRBC) in two consecutive 8-week periods prior to randomization * Refractory to, intolerant to, or ineligible for prior erythropoiesis-stimulating agents (ESAs). * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 Key Exclusion Criteria: * Pregnant or breastfeeding females * Participant has any significant medical illness or is considered vulnerable by local regulations * Prior allogeneic or autologous stem cell transplant * Major surgery within 8 weeks prior to randomization. Note: Other protocol-defined inclusion and exclusion criteria may apply.